Preview

Кардиология

Расширенный поиск

Феномен no-reflow во время первичного чрескожного коронарного вмешательства у пациентов с острым инфарктом миокарда с подъемом сегмента ST, обусловленным массивным коронарным тромбозом. Патогенез и предикторы no-reflow

https://doi.org/10.18087/cardio.2021.2.n1175

Полный текст:

Аннотация

Несмотря на успешную и своевременную реваскуляризацию инфаркт-связанной артерии, у отдельных пациентов ткань миокарда остается в состоянии гипоперфузии. Такое состояние известно как феномен no-reflow и связано с худшим прогнозом. Первая часть систематического обзора феномена no-reflow посвящена описанию его патогенеза и предикторов. Это явление имеет сложный многофакторный патогенез, включающий дистальную эмболизацию, ишемическое повреждение, реперфузионное повреждение, а также компонент индивидуальной предрасположенности. Между тем у ряда пациентов феномен подвергается самопроизвольной регрессии. В ряде исследований продемонстрирована роль определенных биомаркеров и клинических параметров как предикторов риска развития no-reflow. Предполагается, что значимость каждого патогенетического компонента no-reflow у разных пациентов различна, что может служить основой для персонифицированного подхода к лечению.

Об авторах

А. С. Журавлев
ФГАОУ ВО Первый Московский государственный медицинский университет им. И. М. Сеченова Минздрава России (Сеченовский Университет), Москва
Россия
студент 5 курса Международной школы “Медицина Будущего” (Сеченовский Университет)


А. В. Азаров
ФГАОУ ВО Первый Московский государственный медицинский университет им. И. М. Сеченова Минздрава России (Сеченовский Университет), Москва
Россия
кандидат медицинских наук, доцент кафедры интервенционной кардиоангиологии ИПО ФГАОУ ВО Первый МГМУ им И.М. Сеченова МЗ РФ (Сеченовский Университет), заведующий отделением инновационных рентгенхирургических методов диагностики и лечения


С. П. Семитко
ФГАОУ ВО Первый Московский государственный медицинский университет им. И. М. Сеченова Минздрава России (Сеченовский Университет), Москва
Россия
доктор медицинских наук, профессор кафедры интервенционной кардиоангиологии ИПО ФГАОУ ВО Первый МГМУ им И.М. Сеченова МЗ РФ (Сеченовский Университет), директор центра


Д. Г. Иоселиани
ФГАОУ ВО Первый Московский государственный медицинский университет им. И. М. Сеченова Минздрава России (Сеченовский Университет), Москва
Россия
академик РАН, доктор медицинских наук, заведующий кафедрой интервенционной кардиоангиологии института профессионального образования ФГАОУ ВО Первый МГМУ им И.М. Сеченова МЗ РФ (Сеченовский Университет)


Список литературы

1. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal. 2018;39(2):119– 77. DOI: 10.1093/eurheartj/ehx393

2. Gupta S, Gupta MM. No reflow phenomenon in percutaneous coronary interventions in ST-segment elevation myocardial infarction. Indian Heart Journal. 2016;68(4):539–51. DOI: 10.1016/j.ihj.2016.04.006

3. De Maria GL, Patel N, Kassimis G, Banning AP. Spontaneous and Procedural Plaque Embolisation in Native Coronary Arteries: Pathophysiology, Diagnosis, and Prevention. Scientifica. 2013;2013:1–15. DOI: 10.1155/2013/364247

4. Galiuto L, Lombardo A, Maseri A, Santoro L, Porto I, Cianflone D et al. Temporal evolution and functional outcome of no reflow: sustained and spontaneously reversible patterns following successful coronary recanalisation. Heart. 2003;89(7):731–7. DOI: 10.1136/heart.89.7.731

5. Hoffmann R, Haager P, Arning J, Christott P, Radke P, Blindt R et al. Usefulness of myocardial blush grade early and late after primary coronary angioplasty for acute myocardial infarction in predicting left ventricular function. The American Journal of Cardiology. 2003;92(9):1015–9. DOI: 10.1016/j.amjcard.2003.07.001

6. Kloner RA, Ganote CE, Jennings RB. The “No-Reflow” Phenomenon after Temporary Coronary Occlusion in the Dog. Journal of Clinical Investigation. 1974;54(6):1496–508. DOI: 10.1172/JCI107898

7. Gimbrone MA, García-Cardeña G. Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis. Circulation Research. 2016;118(4):620–36. DOI: 10.1161/CIRCRESAHA.115.306301

8. Niccoli G, Burzotta F, Galiuto L, Crea F. Myocardial No-Reflow in Humans. Journal of the American College of Cardiology. 2009;54(4):281–92. DOI: 10.1016/j.jacc.2009.03.054

9. Heusch G, Skyschally A, Kleinbongard P. Coronary microembolization and microvascular dysfunction. International Journal of Cardiology. 2018;258(5):17–23. DOI: 10.1016/j.ijcard.2018.02.010

10. Zhou H, He X, Zhuang S, Wang J, Lai Y, Qi W et al. Clinical and procedural predictors of no-reflow in patients with acute myocardial infarction after primary percutaneous coronary intervention. World Journal of Emergency Medicine. 2014;5(2):96–102. DOI: 10.5847/wjem.j.issn.1920-8642.2014.02.003

11. Hori M, Inoue M, Kitakaze M, Koretsune Y, Iwai K, Tamai J et al. Role of adenosine in hyperemic response of coronary blood flow in microembolization. American Journal of Physiology-Heart and Circulatory Physiology. 1986;250(3):H509–18. DOI: 10.1152/ajpheart.1986.250.3.H509

12. Reffelmann T, Kloner RA. The no-reflow phenomenon: A basic mechanism of myocardial ischemia and reperfusion. Basic Research in Cardiology. 2006;101(5):359–72. DOI: 10.1007/s00395-006-0615-2

13. Tranum-Jensen J, Janse MJ, Fiolet WT, Krieger WJ, D’Alnoncourt CN, Durrer D. Tissue osmolality, cell swelling, and reperfusion in acute regional myocardial ischemia in the isolated porcine heart. Circulation Research. 1981;49(2):364–81. DOI: 10.1161/01.RES.49.2.364

14. Yellon DM, Hausenloy DJ. Myocardial Reperfusion Injury. New England Journal of Medicine. 2007;357(11):1121–35. DOI: 10.1056/NEJMra071667

15. Engler RL, Schmid-Schönbein GW, Pavelec RS. Leukocyte capillary plugging in myocardial ischemia and reperfusion in the dog. The American Journal of Pathology. 1983;111(1):98–111. PMID: 6837725

16. Ambrosio G, Tritto I. Reperfusion injury: Experimental evidence and clinical implications. American Heart Journal. 1999;138(2):S69–75. DOI: 10.1016/S0002-8703(99)70323-6

17. Ito BR, Schmid-Schönbein G, Engler RL. Effects of leukocyte activation on myocardial vascular resistance. Blood Cells. 1990;16(1):145– 63. PMID: 2112413 18. Lefer A, Tsao P, Aoki N, Palladino M. Mediation of cardioprotection by transforming growth factor-beta. Science. 1990;249(4964):61–4. DOI: 10.1126/science.2164258

18. Furuichi K, Wada T, Iwata Y, Kokubo S, Hara A, Yamahana J et al. Interleukin-1-dependent sequential chemokine expression and inflammatory cell infiltration in ischemia-reperfusion injury: Critical Care Medicine. 2006;34(9):2447–55. DOI: 10.1097/01.CCM.0000233878.36340.10

19. Niccoli G, Kharbanda RK, Crea F, Banning AP. No-reflow: again prevention is better than treatment. European Heart Journal. 2010;31(20):2449–55. DOI: 10.1093/eurheartj/ehq299

20. Carden DL, Granger DN. Pathophysiology of ischaemia-reperfusion injury. The Journal of Pathology. 2000;190(3):255–66. DOI: 10.1002/(SICI)1096-9896(200002)190:33.0.CO;2-6

21. Skyschally A, Schulz R, Heusch G. Pathophysiology of Myocardial Infarction: Protection by Ischemic Pre- and Postconditioning. Herz Kardiovaskuläre Erkrankungen. 2008;33(2):88–100. DOI: 10.1007/s00059-008-3101-9

22. Ndrepepa G. Improving myocardial injury, infarct size, and myocardial salvage in the era of primary PCI for STEMI. Coronary Artery Disease. 2015;26(4):341–55. DOI: 10.1097/MCA.0000000000000220

23. Madias JE. “Remote Ischemic Postconditioning” for No-Reflow in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction? The American Journal of Cardiology. 2010;105(2):281. DOI: 10.1016/j.amjcard.2009.09.001

24. Hayashi M, Tsutamoto T, Wada A, Maeda K, Mabuchi N, Tsutsui T et al. Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction. Journal of the American College of Cardiology. 2001;37(7):1820–6. DOI: 10.1016/S0735-1097(01)01233-5

25. Hu G, Huang X, Zhang K, Jiang H, Hu X. Anti-inflammatory Effect of B-Type Natriuretic Peptide Postconditioning During Myocardial Ischemia–Reperfusion: Involvement of PI3K/Akt Signaling Pathway. Inflammation. 2014;37(5):1669–74. DOI: 10.1007/s10753-014- 9895-0

26. Montalescot G, Öngen Z, Guindy R, Sousa A, Lu S-Z, Pahlajani D et al. Predictors of outcome in patients undergoing PCI. Results of the RIVIERA study. International Journal of Cardiology. 2008;129(3):379–87. DOI: 10.1016/j.ijcard.2007.07.127

27. Collet J-P, Montalescot G. The acute reperfusion management of STEMI in patients with impaired glucose tolerance and type 2 diabetes. Diabetes and Vascular Disease Research. 2005;2(3):136–43. DOI: 10.3132/dvdr.2005.021

28. Golino P, Maroko PR, Carew TE. The effect of acute hypercholesterolemia on myocardial infarct size and the no-reflow phenomenon during coronary occlusion-reperfusion. Circulation. 1987;75(1):292–8. DOI: 10.1161/01.CIR.75.1.292

29. Schmidt MR, Rasmussen ME, Bøtker HE. Remote Ischemic Conditioning for Patients With STEMI. Journal of Cardiovascular Pharmacology and Therapeutics. 2017;22(4):302–9. DOI: 10.1177/1074248417702481

30. Yip H-K, Chen M-C, Chang H-W, Hang C-L, Hsieh Y-K, Fang C-Y et al. Angiographic Morphologic Features of Infarct-Related Arteries and Timely Reperfusion in Acute Myocardial Infarction: predictors of slow-flow and no-reflow phenomenon. Chest. 2002;122(4):1322– 32. DOI: 10.1378/chest.122.4.1322

31. Niccoli G, Giubilato S, Russo E, Spaziani C, Leo A, Porto I et al. Plasma levels of thromboxane A2 on admission are associated with noreflow after primary percutaneous coronary intervention. European Heart Journal. 2008;29(15):1843–50. DOI: 10.1093/eurheartj/ehn325

32. Iwakura K, Ito H, Kawano S, Shintani Y, Yamamoto K, Kato A et al. Predictive factors for development of the no-reflow phenomenon in patients with reperfused anterior wall acute myocardial infarction. Journal of the American College of Cardiology. 2001;38(2):472–7. DOI: 10.1016/S0735-1097(01)01405-X

33. Uyarel H, Cam N, Okmen E, Kasıkcıoglu H, Tartan Z, Akgul O et al. Level of Selvester QRS score is predictive of ST-segment resolution and 30-day outcomes in patients with acute myocardial infarction undergoing primary coronary intervention. American Heart Journal. 2006;151(6):1239.e1-1239.e7. DOI: 10.1016/j.ahj.2006.03.019

34. Takahashi T, Hiasa Y, Ohara Y, Miyazaki S, Ogura R, Miyajima H et al. Relation Between Neutrophil Counts on Admission, Microvascular Injury, and Left Ventricular Functional Recovery in Patients With an Anterior Wall First Acute Myocardial Infarction Treated With Primary Coronary Angioplasty. The American Journal of Cardiology. 2007;100(1):35–40. DOI: 10.1016/j.amjcard.2007.02.049

35. Huczek Z, Kochman J, Filipiak KJ, Horszczaruk GJ, Grabowski M, Piatkowski R et al. Mean Platelet Volume on Admission Predicts Impaired Reperfusion and Long-Term Mortality in Acute Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention. Journal of the American College of Cardiology. 2005;46(2):284–90. DOI: 10.1016/j.jacc.2005.03.065

36. Campo G, Valgimigli M, Gemmati D, Percoco G, Tognazzo S, Cicchitelli G et al. Value of Platelet Reactivity in Predicting Response to Treatment and Clinical Outcome in Patients Undergoing Primary Coronary Intervention. Journal of the American College of Cardiology. 2006;48(11):2178–85. DOI: 10.1016/j.jacc.2005.12.085

37. Niccoli G, Lanza GA, Shaw S, Romagnoli E, Gioia D, Burzotta F et al. Endothelin-1 and acute myocardial infarction: a no-reflow mediator after successful percutaneous myocardial revascularization. European Heart Journal. 2006;27(15):1793–8. DOI: 10.1093/eurheartj/ehl119

38. Iwakura K, Ito H, Ikushima M, Kawano S, Okamura A, Asano K et al. Association between hyperglycemia and the no-reflow phenomenon inpatients with acute myocardial infarction. Journal of the American College of Cardiology. 2003;41(1):1–7. DOI: 10.1016/S0735-1097(02)02626-8

39. Karila-Cohen D, Czitrom D, Brochet E, Faraggi M, Seknadji P, Himbert D et al. Decreased no-reflow in patients with anterior myocardial infarction and pre-infarction angina. European Heart Journal. 1999;20(23):1724–30. DOI: 10.1053/euhj.1999.1714

40. Yalcin A, Biyik I, Akturk F, Hancer VS, Yalcin B, Tosu AR et al. Association between Endothelial Nitric Oxide Synthase Gene Polymorphism (Glu298Asp) and Coronary No-Reflow Phenomenon in Acute Myocardial Infarction. Advances in Hygiene & Experimental Medicine. 2019; [Epub ahead of print]. DOI: 10.5604/01.3001.0013.5253

41. Limbruno U, De Carlo M, Pistolesi S, Micheli A, Sonia Petronio A, Camacci T et al. Distal embolization during primary angioplasty: Histopathologic features and predictability. American Heart Journal. 2005;150(1):102–8. DOI: 10.1016/j.ahj.2005.01.016

42. Nallamothu BK, Bradley EH, Krumholz HM. Time to Treatment in Primary Percutaneous Coronary Intervention. New England Journal of Medicine. 2007;357(16):1631–8. DOI: 10.1056/NEJMra065985

43. Turschner O. The sequential changes in myocardial thickness and thickening which occur during acute transmural infarction, infarct reperfusion and the resultant expression of reperfusion injury. European Heart Journal. 2004;25(9):794–803. DOI: 10.1016/j.ehj.2004.01.006

44. Matsumoto H, Inoue N, Takaoka H, Hata K, Shinke T, Yoshikawa R et al. Depletion of antioxidants is associated with no-reflow phenomenon in acute myocardial infarction: Antioxidants depletion associated with no-reflow phenomenon. Clinical Cardiology. 2004;27(8):466– 70. DOI: 10.1002/clc.4960270809

45. Galiuto L, DeMaria AN, del Balzo U, May-Newman K, Flaim SF, Wolf PL et al. Ischemia-Reperfusion Injury at the Microvascular Level: Treatment by Endothelin A–Selective Antagonist and Evaluation by Myocardial Contrast Echocardiography. Circulation. 2000;102(25):3111–6. DOI: 10.1161/01.CIR.102.25.3111

46. Zalewski J, Undas A, Godlewski J, Stepien E, Zmudka K. No-Reflow Phenomenon After Acute Myocardial Infarction Is Associated With Reduced Clot Permeability and Susceptibility to Lysis. Arteriosclerosis, Thrombosis, and Vascular Biology. 2007;27(10):2258–65. DOI: 10.1161/ATVBAHA.107.149633

47. Niccoli G, Altamura L, Fabretti A, Lanza GA, Biasucci LM, Rebuzzi AG et al. Ethanol Abolishes Ischemic Preconditioning in Humans. Journal of the American College of Cardiology. 2008;51(3):271–5. DOI: 10.1016/j.jacc.2007.09.042


Для цитирования:


Журавлев А.С., Азаров А.В., Семитко С.П., Иоселиани Д.Г. Феномен no-reflow во время первичного чрескожного коронарного вмешательства у пациентов с острым инфарктом миокарда с подъемом сегмента ST, обусловленным массивным коронарным тромбозом. Патогенез и предикторы no-reflow. Кардиология. 2021;61(2):99-105. https://doi.org/10.18087/cardio.2021.2.n1175

For citation:


Zhuravlev A.S., Azarov A.V., Semitko S.P., Ioseliani D.G. The no-Reflow Phenomenon During Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction due to Massive Coronary Thrombosis. Pathogenesis and Predictors of no-Reflow. Kardiologiia. 2021;61(2):99-105. (In Russ.) https://doi.org/10.18087/cardio.2021.2.n1175

Просмотров: 1076


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 0022-9040 (Print)
ISSN 2412-5660 (Online)